December 2022

Studies highlight use and sequencing of BTK inhibitors, CAR T-cell therapy, and natural killer (NK) cell therapy.

Reports focus on Medicare's cuts to Physician Fee Schedule and the American Medical Association' update on pharmacy benefit managers.

Coverage of FDA approvals for teclistamab, the first bispecific antibody in multiple myeloma; tremelimumab and durvalumab in liver cancer; cemiplimab with chemotherapy in first-line NSCLC; and mirvetuximab soravtansine-gynx for platinum-resistant ovarian cancer.

Coverage from the first day of the inaugural OneOncology Physician Leadership Conference, held November 11-13, 2022, in Nashville, Tennessee.

Coverage from the Community Oncology Alliance Payer Exchange Summit, held in Tyson's Corner, Virginia, October 24-25, 2022.

The Association of Community Cancer Centers' 39th National Oncology Conference took place October 12-14 in West Palm Beach, Florida.

Coverage from the Institute for Value-Based Medicine® event with Oncology Consultants of Houston, held in Texas on October 11, 2022.

Coverage from the Institute for Value-Based Medicine® event in Denver, Colorado, held October 5, 2022. The event was held in partnership with Rocky Mountain Cancer Centers.

Lucy Langer, MD, MSHS, national medical director, oncology and genomics, MSHS, national medical director, oncology and genomics, UnitedHealthcare, discussed value-based contracting at the IVBM® session October 5, 2022.

Coverage from the Institute for Value-Based Medicine® event in Nashville, Tennessee, held November 17, 2022. The event was held in partnership with Vanderbilt-Ingram Cancer Center.

Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.

Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.

Alexander Spira, MD, PhD, a medical oncologist and director of VCS Research Institute & Phase I Trial Program, Virginia Cancer Specialists, discusses unmet needs and treatment with KRAS-mutated non–small cell lung cancer (NSCLC).

Beveridge, now with Avalere Health, addressed the importance of clinical pathways in selecting therapies in non-small cell lung cancer (NSCLC) and the emergence of options for EGFR Exon 20 Insertion+ NCSLC.